Nanexa enters EUR 1.165 billion global licensing deal with Novo Nordisk for long-acting injectables

Bitget2026/09/24 16:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nanexa entered a global exclusive license and collaboration agreement with Novo Nordisk for its PharmaShell drug-delivery platform.
Deal targets long-acting injectable peptide drugs for obesity, type 2 diabetes, and other cardiometabolic indications.
Novo secured rights for up to five development programs, aiming for monthly and quarterly dosing profiles.
Nanexa is eligible for up to EUR 1.165 billion, including EUR 615 million in upfront and development and regulatory milestones.
Agreement also includes sales milestones and low single-digit royalties on future product sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanexa AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nanexa enters EUR 1.165 billion global licensing deal with Novo Nordisk for long-acting injectables

You may also like

Crypto prices